The Delaware Court of Chancery has granted New York-based Bioenvision Inc. permission to reconvene a special stockholders meeting to vote again on Cambridge-based Genzyme Corp.‘s proposed $345 million purchase of the company.
The do-over will take place Oct. 22, and is an opportunity “for those votes to be properly counted,” according to the companies. The original stockholders meeting was held Oct. 5. Any stockholder may vote, or change his or her vote, during the Oct. 22 meeting.
The companies said 55 percent of stockholders voted in favor of the merger Oct. 5.
Bioenvision is a developer of cancer drugs. Genzyme is a biotechnology company focused on the treatment of serious diseases.
